Disc Medicine Secures $200M Financing for Hematology Pipeline
Company Announcements

Disc Medicine Secures $200M Financing for Hematology Pipeline

Disc Medicine ( (IRON) ) has shared an update.

Disc Medicine has secured a $200 million non-dilutive debt financing from Hercules Capital to enhance its financial flexibility and support the development of its hematology pipeline. This funding will aid key projects, including a potential confirmatory study of bitopertin and other clinical trials. The loan offers up to 60 months of interest-only payments, providing Disc with strategic options to advance its novel treatments for hematologic diseases.

For detailed information about IRON stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyDisc Medicine secures $200M in non-dilutive debt financing
TheFlyDisc Medicine price target raised to $70 from $62 at Scotiabank
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App